Abstract: In 1988, the first contrast agent specifically designed for magnetic resonance imaging (MRI), gadopentetate dimeglumine (Magnevist and contrast media development, to highlight certain key advances in the clinical development of CE-MRI, to outline current technical trends and clinical challenges, and to suggest some important future perspectives.
INTRODUCTION
The year 2013 heralded the 25th anniversary of contrast enhancement in magnetic resonance imaging (MRI). The first gadolinium-based contrast agent (GBCA), gadopentetate dimeglumine (Magnevist 
CONCEPT OF MRI AND EARLY CONTRAST MEDIA RESEARCH
The phenomenon that came to be known as nuclear magnetic resonance (NMR) was discovered by Bloch, Bloembergen and Purcell in the 1940s [1, 2] . The first NMR images to be generated using the interaction of two magnetic gradients were not published, however, until 
MODE OF ACTION AND PHARMACOLOGY OF GBCAS
All GBCAs contain the paramagnetic ion of the rare earth metal gadolinium (Gd 3? ), which possesses the most unpaired electrons of any stable ion (seven), creating a high magnetic moment that is effective at enhancing proton relaxation [23, 24] . Paramagnetic contrast media shorten the T1 (longitudinal) and T2 
KEY ADVANCES IN CE-MRI INDICATIONS
The field of CE-MRI has undergone extensive development [77]-examples of major advances are described in the following sections.
Central Nervous System
Early studies during GBCA development showed that CE-MRI had utility for brain imaging [17] due to the possibility to enhance areas with a disrupted blood-brain barrier corresponding to 
Magnetic Resonance Angiography
In the early 1990s, the imaging technique of contrast-enhanced MRA was described providing information on the anatomy of the heart and the large blood vessels (including the coronary artery), ventricular wall motion, cardiac function, the heart valves, myocardial perfusion, myocardial viability and cardiac metabolism.
Today, cardiac MRI has the capability to visualize cardiac function and morphology, and has become a standard imaging modality in a range of clinical applications including assessment of valvular disease, myocarditis and cardiomyopathies, and congenital heart disease [125, 126] .
Abdomen
The first CE-MRI examination of the liver was performed in 1984, as part of a case series investigating the efficacy and safety of gadopentetate dimeglumine-enhanced MRI [22] . Assessment of the dynamic CE-MRI enhancement pattern has become key for the differentiation of benign and malignant lesions in the liver, pancreas and kidneys, as well as elsewhere in the body [127] . Major advances in this field were the introduction of fast breath-hold techniques and effective respiratory triggering, which reduced respiratory-and motion-induced artifacts while improving the sensitivity of imaging [128] [129] [130] .
Another major advance was the advent of hepato-specific contrast agents. The first liver-specific CE-MRI results were published in 1991, describing manganese dipyridoxal diphosphate enhancement of the liver parenchyma and clearance into the gallbladder (this agent has currently limited worldwide availability) [131] . Gadobenate dimeglumine was then demonstrated to exhibit a small amount of hepatic excretion in humans (3-5%) [132] , meaning that a liver-specific imaging phase could be discerned during delayed imaging (1-2 h p.i.).
The agent gadoxetic acid (primovist/eovist) was developed as a highly liver-specific contrast medium. Gadoxetic acid is excreted almost equally via the liver and kidneys in humans and provides an earlier hepato-specific imaging time (15-20 min p.i.) compared with gadobenate [133] . A seminal manuscript by Weinmann, published in 1991, described the preclinical results for gadoxetic acid, highlighting its protein binding properties, low toxicity and uptake properties in rat hepatocytes, predicting gadoxetic acid to play a future role as a hepatobiliary contrast agent for MRI in clinical practice [134] . The clinical trials in humans that followed established the value of gadoxetic acid for liver MRI, and more specifically for the detection and differentiation of focal liver lesions in the cirrhotic and noncirrhotic liver (Fig. 4) [138, 139] . The potential utility of gadoxetic acid-enhanced MRI has also been suggested for the assessment of the liver pre-and post-treatment (surgery or locoregional therapy), including the quantitative and regional assessment of liver function [140] [141] [142] [143] .
Contrast-enhanced magnetic resonance imaging has also proven useful, alongside multidetector CT, for accurate and sensitive characterization of renal masses; however, MRI has shown particular value as a problem-solving tool in this field, and advanced techniques, such as perfusion and diffusion imaging, are now being investigated for the assessment of renal lesions and renal function (MR nephrography) [144, 145] .
CE-MR enterography for imaging the small bowel provides similar spatial resolution and Fig. 4 Magnetic resonance imaging of the liver in a patient with chronic hepatitis C. Images a and b show pre-contrast T2-and T1-weighted images, respectively; images c-f were obtained 20 s, 1, 5 and 25 min, respectively, after injection of gadoxetic acid. A lesion in segment VII of the liver demonstrates hyperintensity on pre-contrast T2-weighted image, and hypointensity on T1. Post-contrast, the mass has peripheral puddling of contrast in the arterial phase (c) which progressively coalesce (d, e). In the hepatocyte phase (f), the mass is hypointense to the liver with similar signal intensity to blood vessels. Imaging features are characteristic of haemangioma [135] . Reprinted from Cruite et al. [135] , with permission from the American Journal of Roentgenology improved contrast resolution compared to CT for investigation of gastrointestinal tumors and inflammatory bowel disease [146] , and it shows promise for the future in terms of differentiating active from chronic bowel disease and non-invasive monitoring of response to therapy [147] . [162, 163] .
Musculoskeletal System
Magnetic resonance imaging has been used to image the musculoskeletal system since the early days of the modality, as MRI demonstrated good soft tissue contrast, spatial resolution and multi-planar capabilities, and sequences could be adapted for optimal contrast between muscle, bone marrow and abnormal tissue [164] . The indications for musculoskeletal MRI fall into three main categories: tumors, infectious diseases and joint damage [165] . CE-MRI is employed to gain additional information in cases of complicated osseous and soft-tissue infection (especially when extent and necrosis are of concern), and for the evaluation of articular injuries and post-operative joint status [165] . For joint assessment, MR arthrography has become a useful alternative to conventional MRI, with GBCA administration performed intravenously (indirect arthrography) or into the target joint (direct arthrography) [166] strength has also brought possibilities for higher image quality and shorter scan times [168] .
CURRENT TECHNOLOGICAL TRENDS AND CLINICAL CHALLENGES
The growing importance of MRI as a diagnostic tool has been underpinned by its capacity for multiparametric data acquisition, including DWI, DCE, elastography and MR spectroscopy, alongside conventional MRI protocols.
Multiparametric imaging has enabled more accurate assessment of normal and disease-associated tissue characteristics in terms of cellularity (diffusion restriction), vascularization (DSC), permeability (DCE), fibrosis and metabolite levels, leading to greater certainty of diagnosis and improved patient outcome. Multiparametric MRI is advancing imaging capabilities in many fields, with a special focus on indications where anatomical imaging alone has in the past been associated with limited accuracy, such as breast and prostate cancer imaging [169] . A recent trend in the development of MRI has been the investigation of integrated multimodality imaging, particularly MR/PET [170] . While PET/CT has been established as a diagnostic tool in cancer imaging for the past decade, MR/ PET offers exciting possibilities for gathering extensive morphologic and hybrid (i.e. both PET and MRI) functional information. More research is required to establish the most appropriate clinical applications of MR/PET, based on diagnostic performance, technical feasibility, practicality and cost in relation to existing techniques [170] . MR/PET techniques will also require changes in data acquisition, data processing, and image processing and interpretation when compared with PET/CT [171] .
The The role of CE-MRI in disease screening programs is an ongoing topic of discussion, with both health-economic and clinical repercussions. CE-MRI has demonstrated high sensitivity and specificity for the detection of liver cancer [173] and, as discussed above, CE-MRI of the breast provides a high cancer yield and is recommended for screening women at high risk [160, 162] . Currently, the imaging time and cost of a standard CE-MRI examination limits the use of MRI in screening programs. However, the feasibility of an MRI examination that uses limited sequences but retains sufficient sensitivity for screening is under discussion. This approach could shift the role of MRI in screening, decrease the cost per MRI examination and make MRI screening more cost-effective [174] .
FUTURE PERSPECTIVES
As the field of CE-MRI expands, there are many current research avenues and trends that in the future could prove important to clinical practice. In the following sections, four of these potentially interesting areas are discussed; however, we acknowledge that many more exciting avenues exist. dataset per second) [175] , functional cardiac MRI of the whole heart within one breath hold [176] or using a free breathing technique [177] , and high-resolution dynamic liver imaging at four frames per second [178, 179] .
This approach is likely to have an impact in many areas, initially for dynamic processes but eventually for all clinical MRI procedures, leading to an improved patient care through shorter and less invasive diagnostic examinations.
Role of Contrast Agents
Contrast media will be indispensable in most MRI examinations in the foreseeable future. The type of contrast medium selected and the dose that is injected will likely reflect changes in knowledge and techniques. Greater availability of MRI scanners with extended field of view coils and a 3 T field strength has provided an opportunity to improve the sensitivity of imaging and to allow contrast dose reduction without compromising image quality [180] . 
Higher Relaxivity Contrast Agents
Despite the major advances in CE-MRI in recent times, there are pathologies that cannot be fully assessed by MRI. In order to increase the sensitivity of CE-MRI in certain pathologies, contrast agents with substantially higher relaxivity will be required.
The efficiency of GBCAs, defined by their T1-relaxivity, is in part dependent on the number of water molecules directly bound to the Gd 3? complex (q), their mean residence time (s m ) and the number and residence times of water molecules in the second hydration sphere (Fig. 6 ) [181] . GBCAs induce proton relaxation by creating a fluctuating magnetic field, which can arise from tumbling of the molecule in solution (described by the rotational correlation time, s R ) and excitation and relaxation of electrons in the Gd 3? (Fig. 6) [181]. Molecular size, rigidity of the At typical clinical magnetic field strengths (0.5-3 T), the greatest increases of T1-relaxivity for GBCAs have been achieved by slowing the tumbling (increasing s R ) of complexes with q = 1 and water exchange rates (s m ) of 10-30 ns [182] . Relaxivity can be increased further by increasing q to 2; however, this reduces the stability of the complex. Water exchange dynamics and relaxivity can also be adapted by altering groups of atoms within the however, such water residence times would be close to the shortest currently observed (1 ns) [182] . The best strategy for raising relaxivity at high field strength is probably a moderate reversible binding to plasma proteins, a large second sphere of water molecules surrounding the Gd-complex, and an increase in q; however, the benefits of the latter modification should be weighed against any reduction in complex stability. A number of studies using q = 2 and q = 3 have investigated this concept [182] .
Fig. 6 Schematic diagram of a gadolinium contrast agent molecular complex, and intrinsic factors affecting its T1-relaxivity

Applications of Higher Relaxivity Contrast Agents
Targeted Imaging Significant increases in relaxivity will allow substantial reductions in dose for novel agents and will facilitate the development of targeted/ tissue-specific contrast media. Tissue-specific contrast agents are already available, such as gadoxetic acid, which is taken up by a hepatocyte uptake transporter (organic anion-transporting polypeptide 8) in liver parenchyma [189] , and the superparamagnetic iron oxide particles (SPIOs), which are sequestered by phagocytic Kupffer cells in the reticuloendothelial system of the liver [190] . Other targeted agent approaches are at an experimental stage: investigations of ultrasmall SPIOs for imaging macrophage activity in lymph nodes and atherosclerotic plaque have been performed, as has labeling of tumors with monoclonal antibodies conjugated to paramagnetic complexes or superparamagnetic nanoparticles [191] . However, the sensitivities of these techniques are not currently adequate for clinical applications, and new agents with significantly increased relaxivity targeted to specific tissues or disease processes will be required. One such experimental agent is EP-2104R, a molecule containing four Gd-complexes that binds with good specificity to fibrin, where it demonstrates a relaxivity per molecule approximately 25 times higher than a conventional GBCA at 1.4 T [192] . The strong fibrin binding, selectivity and high relaxivity of EP-2104R enabled a clear depiction of occlusive intracranial thrombi in a rat embolic stroke model, where the Gd 3? concentration in the clot was 18-fold higher than in the blood pool [193] . This agent has also demonstrated good visualization of thrombi in a swine model of pulmonary embolism [194] , and could depict thrombi in the arterial and venous systems and hearts of patients [195, 196] .
Monitoring Response to Therapy
Early information on disease progression and response to therapy has considerable potential benefits for patient management, by promptly highlighting a need to shift therapeutic approaches and by providing cost savings if expensive therapies (e.g., anti-angiogenic agents) are quickly evaluated to be unsuccessful.
A number of quantitative DCE and perfusion parameters are now considered biomarkers with value for the prediction and monitoring of therapeutic response, particularly to date in the oncologic and cardiologic specialties [197] [198] [199] .
For example, in oncology, perfusion mapping (as a surrogate measure of blood flow) correlates with response to tyrosine-kinase inhibitor therapy in patients with renal tumors [200] , and quantitative kinetic parameters of lesion enhancement at DCE can predict whether triple-negative breast cancer patients will respond to neoadjuvant chemotherapy [201] . Animal studies have suggested that quantitative tumor vascularity and perfusion parameters can act as surrogate descriptors for the effect of sorafenib therapy on prostate carcinoma within a week [172] and that, in conjunction with novel contrast agents, the DCE MRI profile is able to indicate early (within 24 h) endothelial permeability changes following bevacizumab therapy in a melanoma model [202] . 
